Axovant Completes $362 Million IPO

Palo Alto – June 16, 2015 – Cooley advised Axovant Sciences Ltd. on its $362.3 million initial public offering. Axovant is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company now trades on the New York Stock Exchange under the symbol "AXON."

The Cooley corporate securities team advising Axovant included partners Frank Rahmani, John McKenna and Div Gupta, special counsel Brian Leaf and associates Ali Haggerty, Mark Ballantyne and Jason Saxe.

Support for the offering was provided by partner Marya Postner and associate Jennifer Raab (life sciences corporate partnering); partners Ivor Elrifi and Heidi Erlacher (intellectual property); partner Renee Deming (compensation and benefits); partner Seth Rafkin (employment and labor); partners Jeremy Naylor and Aaron Pomeroy (tax); and partners Wendy Goldstein and Natasha Leskovsek (health care and life sciences regulatory).

About Cooley LLP

High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters. Where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
John McKenna  Partner Palo Alto
Marya Postner  Partner Palo Alto
Brian Leaf  Partner Reston
Aaron Pomeroy  Partner Colorado
Natasha Leskovsek  Of Counsel Washington, DC
Renee Deming  Retired Partner Palo Alto
Jennifer Raab  Special Counsel Palo Alto
Mark Ballantyne  Partner Reston
Div Gupta  Partner New York
Ivor Elrifi  Partner New York, Boston
Heidi A. Erlacher  Partner in Charge – Boston Boston